Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease

Grove, A.; Lipworth, B. J.; Reid, P.; Smith, R. P.; Ramage, L.; Ingram, C. G.; Jenkins, R. J.; Winter, J. H.; Dhillon, D. P.
July 1996
Thorax;Jul1996, Vol. 51 Issue 7, p689
Academic Journal
No abstract available.


Related Articles

  • Chronic Obstructive Pulmonary Disease.  // Current Medical Literature: Respiratory Medicine;2008, Vol. 22 Issue 1, p11 

    This article presents abstracts of research on to chronic obstructive pulmonary diseases (COPD) published in various journals including "Effect of Salmeterol/Fluticasone Propionate on Airway Inflammation in COPD: A Randomized Controlled Trial," "Effect of Occupational Exposure on Decline of Lung...

  • Efficacy of Inhaled Fluticasone Plus Salmeterol in COPD. Miller, Karl E. // American Family Physician;5/1/2004, Vol. 69 Issue 9, p2239 

    Deals with the findings of a study on the efficacy of fluticasone propionate and salmeterol in patients with chronic obstructive pulmonary disease (COPD). Use of bronchodilators as first-line therapy treatment for COPD; Effect of inhaled corticosteroids in patients with COPD; Effectiveness of...

  • Long-Acting β Agonists in the Management of Stable Chronic Obstructive Pulmonary Disease. Cazzola, M.; Donner, C.F. // Drugs;Aug2000, Vol. 60 Issue 2, p307 

    Long-acting β agonist bronchodilators (e.g. formoterol, salmeterol) are a new interesting therapeutic option for patients with chronic obstructive pulmonary disease (COPD). In the short term, both salmeterol and formoterol appear to be more effective than short-acting β agonists, and in...

  • Effect of Terbutaline on Exercise Capacity and Pulmonary Function in Patients with Chronic... Iversen, E.T.; Sorensen, T.; Heckscher, T.; Jensen, J.I. // Lung;1999, Vol. 177 Issue 4, p263 

    Investigates the effects of a single dose of terbutaline on resting lung function and exercise capacity in patients with chronic obstructive lung disease. Achievement of respiratory exchange ratio higher than one in both days; Non-occurrence of changes in the peak work rate; Change in the peak...

  • Controlled trial supervised exercise training in chronic bronchitis. Sinclair, D.J.M.; Ingram, C.G. // British Medical Journal;2/23/1980, Vol. 280 Issue 6213, p519 

    Examines the effectiveness of supervised exercise training for chronic bronchitis patients. Improvement in walking distance of patients; Changes in the cardiorespiratory function; Benefits of exercise rehabilitation for patients with obstructive lung disease.

  • Salmeterol/Fluticasone Propionate: A Review of its Use in the Treatment of Chronic Obstructive Pulmonary Disease. Keating, Gillian M.; McCormack, Paul L. // Drugs;2007, Vol. 67 Issue 16, p2383 

    Salmeterol/fluticasone propionate (Seretide®, Advair®, Viani®) administered using a multidose dry powder inhaler (Diskus®, Accuhaler®) is approved for use in the treatment of chronic obstructive pulmonary disease (COPD) in numerous countries. Salmeterol/fluticasone propionate...

  • Inhalation of β2 agonists impairs the clearance of nontypable Haemophilus influenzae from the murine respiratory tract. Maris, Nico A.; Florquin, Sandrine; Van't Veer, Cornelis; De Vos, Alex F.; Buurman, Wim; Jansen, Henk M.; Van der Poll, Tom // Respiratory Research;2006, Vol. 7, p1 

    Background: Nontypable Haemophilus influenzae (NTHi) is a common bacterial pathogen causing human respiratory tract infections under permissive conditions such as chronic obstructive pulmonary disease. Inhalation of β2-receptor agonists is a widely used treatment in patients with chronic...

  • Inhaled Salmeterol: A Review of its Efficacy in Chronic Obstructive Pulmonary Disease. Jarvis, B.; Markham, A. // Drugs & Aging;2001, Vol. 18 Issue 6, p441 

    Inhaled salmeterol is a long-acting, selective β-adrenoceptor agonist bronchodilator. The drug has been compared with placebo, ipratropium bromide and oral theophylline in patients with chronic obstructive pulmonary disease (COPD) in randomised, clinical trials. Inhaled salmeterol 50µg...

  • Long acting β2 agonists for stable chronic obstructive pulmonary disease with poor reversibility: a systematic review of randomised controlled trials. Husereau, Don; Shukla, Vijay; Boucher, Michel; Mensinkai, Shaila; Dales, Robert // BMC Pulmonary Medicine;2004, Vol. 4, p1 

    Background: The long acting β2-agonists, salmeterol and formoterol, have been recommended, by some, as first line treatment of stable chronic obstructive pulmonary disease (COPD). We reviewed evidence of efficacy and safety when compared with placebo or anticholinergic agents in patients with...

  • A Benefit-Risk Assessment of Inhaled Long-Acting β2-Agonists in the Management of Obstructive Pulmonary Disease. Sovani, Milind P; Whale, Christopher I.; Tattersfield, Anne. E // Drug Safety;2004, Vol. 27 Issue 10, p689 

    The two inhaled long-acting β2-adrenoceptor agonists, salmeterol and formoterol, have been studied extensively since their introduction in the early 1990s. In this review we consider the evidence for their efficacy and safety in adults with asthma and chronic obstructive pulmonary disease...


Read the Article


Sign out of this library

Other Topics